{"id":"NCT01665599","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel","officialTitle":"A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-04","completion":"2013-05","firstPosted":"2012-08-15","resultsPosted":"2017-09-20","lastUpdate":"2017-10-26"},"enrollment":180,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adult Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone gel (FE 999303)","otherNames":[]}],"arms":[{"label":"Testosterone gel (FE 999303)","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3 clinical trial in adult hypogonadal males with baseline serum testosterone concentrations \\<300 ng/dL. The purpose of this study is to evaluate the safety and efficacy of testosterone gel (2%) delivered using an applicator.","primaryOutcome":{"measure":"The Percentage of Subjects on Day 90 Whose Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL","timeFrame":"Day 90","effectByArm":[{"arm":"Testosterone Gel (FE 999303)","deltaMin":2.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":180},"commonTop":["Upper respiratory tract infection","Blood triglycerides increased","Prostatic specific antigen increased","Rash","Hypertension"]}}